Tessera Therapeutics is pioneering Gene Writing to cure disease. Our genome is a mosaic comprising genes that protect us from, predispose us to, and cause disease. Gene Editing biotechnologies heralded the era of genome-modifying medicines, but they cannot address most diseases. Gene Writing is a new biotechnology that writes therapeutic messages into the genome to cure thousands of diseases at their source.
Tessera Therapeutics was founded by Flagship Pioneering, an innovation enterprise that conceives, creates, resources, and grows first-in-category life sciences companies. Flagship Pioneering has created over 40 groundbreaking companies over the past fifteen years, all of which are pioneering novel and proprietary biological, industrial, and engineering approaches to solve major needs in human health and sustainability. These companies include Seres Therapeutics (NASDAQ:MCRB), Moderna (MRNA), Syros Pharmaceuticals (SYRS), Rubius Therapeutics (RUBY), Axcella Health (AXLA), Evelo Biosciences (EVLO), and Indigo Agriculture.